1. TERT promoter mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic glioma with molecular features of glioblastoma
- Author
-
Kenji, Fujimoto, Hideyuki, Arita, Kaishi, Satomi, Kai, Yamasaki, Yuko, Matsushita, Taishi, Nakamura, Yasuji, Miyakita, Toru, Umehara, Keiichi, Kobayashi, Kaoru, Tamura, Shota, Tanaka, Fumi, Higuchi, Yoshiko, Okita, Yonehiro, Kanemura, Junya, Fukai, Daisuke, Sakamoto, Takehiro, Uda, Ryunosuke, Machida, Aya, Kuchiba, Taketoshi, Maehara, Motoo, Nagane, Ryo, Nishikawa, Hiroyoshi, Suzuki, Makoto, Shibuya, Takashi, Komori, Yoshitaka, Narita, and Koichi, Ichimura
- Subjects
Adult ,Male ,DNA Copy Number Variations ,Brain Neoplasms ,Homozygote ,PTEN Phosphohydrolase ,Glioma ,Middle Aged ,Isocitrate Dehydrogenase ,Mutation ,Humans ,Female ,Telomerase ,Sequence Deletion - Abstract
The Consortium to Inform Molecular and Practical Approaches to CNS Tumor Taxonomy (cIMPACT-NOW) update 3 recommends that histologic grade II and III IDH-wildtype diffuse astrocytic gliomas that harbor EGFR amplification, the combination of whole chromosome 7 gain and whole chromosome 10 loss (7 + /10 -), or TERT promoter (pTERT) mutations should be considered as glioblastomas (GBM), World Health Organization grade IV. In this retrospective study, we examined the utility of molecular classification based on pTERT status and copy-number alterations (CNAs) in IDH-wildtype lower grade gliomas (LGGs, grade II, and III). The impact on survival was evaluated for the pTERT mutation and CNAs, including EGFR gain/amplification, PTEN loss, CDKN2A homozygous deletion, and PDGFRA gain/amplification. We analyzed 46 patients with IDH-wildtype/pTERT-mutant (mut) LGGs and 85 with IDH-wildtype/pTERT-wildtype LGGs. EGFR amplification and a combination of EGFR gain and PTEN loss (EGFR + /PTEN -) were significantly more frequent in pTERT-mut patients (p 0.0001). Cox regression analysis showed that the pTERT mutation was a significant predictor of poor prognosis (hazard ratio [HR] 2.79, 95% confidence interval [CI] 1.55-4.89, p = 0.0008), but neither EGFR amplification nor EGFR + /PTEN - was an independent prognostic factor in IDH-wildtype LGGs. PDGFRA gain/amplification was a significant poor prognostic factor in IDH-wildtype/pTERT-wildtype LGGs (HR 2.44, 95% CI 1.09-5.27, p = 0.03, Cox regression analysis). The IDH-wildtype LGGs with either pTERT-mut or PDGFRA amplification were mostly clustered with GBM by DNA methylation analysis. Thus, our study suggests that analysis of pTERT mutation status is necessary and sufficient to diagnose IDH-wildtype diffuse astrocytic gliomas with molecular features of glioblastoma. The PDGFRA status may help further delineate IDH-wildtype/pTERT-wildtype LGGs. Methylation profiling showed that IDH-wildtype LGGs without molecular features of GBM were a heterogeneous group of tumors. Some of them did not fall into existing categories and had significantly better prognoses than those clustered with GBM.
- Published
- 2021